Silk Road Medical (FRA:2OW) Cash, Cash Equivalents, Marketable Securities : €160.5 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical Cash, Cash Equivalents, Marketable Securities?

Silk Road Medical's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (€180.71 Mil) to Dec. 2023 (€166.41 Mil) but then stayed the same from Dec. 2023 (€166.41 Mil) to Mar. 2024 (€160.51 Mil).

Silk Road Medical's annual cash, cash equivalents, marketable securities increased from Dec. 2021 (€97.55 Mil) to Dec. 2022 (€201.71 Mil) but then declined from Dec. 2022 (€201.71 Mil) to Dec. 2023 (€166.41 Mil).

Silk Road Medical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Silk Road Medical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical Cash, Cash Equivalents, Marketable Securities Chart

Silk Road Medical Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

81.62

121.23

97.55

201.71

166.41

Silk Road Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															176.59	173.86	180.71	166.41	160.51

Silk Road Medical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Silk Road Medical (FRA:2OW) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Silk Road Medical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Silk Road Medical (FRA:2OW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (FRA:2OW) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

SILK:USA

Address

1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089

Website

https://www.silkroadmed.com

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical (FRA:2OW) Headlines

No Headlines